On June 14, 2021 Genmab reported the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program (Press release, Genmab, JUN 14, 2021, View Source [SID1234583956]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares.

The following transactions were executed under the program from June 7, 2021 to June 11, 2021:

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 273,606 shares as treasury shares, corresponding to 0.42% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 11 dated February 23, 2021.

On June 14, 2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high potency, fully-human polyclonal antibodies at scale, reported that Eddie J. Sullivan, PhD, co-founder, president, CEO, will serve as an expert panelist during BIO Digital 2021 (Press release, SAB Biotherapeutics, JUN 14, 2021, View Source [SID1234583972]). The panel, "One Health Preparedness and Response: Translating Surveillance of Emerging Zoonotic Diseases into Biotechnology," will be moderated by Catherine Machalaba, MPH, PhD, senior policy advisor and senior scientist at EcoHealth Alliance. The panel is scheduled on Monday, June 14, 2021, from 11:05 AM to 11:50 AM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One Health, or the concept that animal, human, and environmental health are interconnected, has been made readily apparent by the recent COVID-19 pandemic. The World Health Organization estimates that more than 60% of human diseases are zoonotic and that 75% of diseases discovered over the past decade originate in animals. The panelists, who include public health experts and Company leaders, will examine how the biotechnology industry can contribute to solutions to ensure the world is prepared for continuing zoonotic threats to human health.

Dr. Sullivan commented, "We have spent nearly two decades at SAB developing and optimizing our unique platform that leverages transgenic cows to rapidly produce large quantities of highly potent, fully-human therapeutic polyclonal antibodies targeted at specific diseases. Responding to the COVID-19 pandemic has provided us the opportunity to fully integrate and accelerate scale-up of our drug development, regulatory and production capabilities. We look forward to sharing what we have learned and providing a model for future response with our colleagues committed to applying 21st century biotechnology to combat these ongoing threats to global well-being."

About BIO:

BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. For more information on BIO Digital 2021, visit www.bio.org/events/bio-digital.

On June 14, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that Dr. Brian Schwartz will present a summary of recent eganelisib clinical data followed by a Q&A session at the Keystone Symposia Precision Oncology: Translating Discovery to the Clinic Meeting taking place on June 21, 2021 (Press release, Infinity Pharmaceuticals, JUN 14, 2021, View Source [SID1234583957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title:

Eganelisib (IPI-549) Activity as a Macrophage Reprogramming Therapeutic Candidate in 1L Metastatic TNBC, 2L Metastatic Urothelial Cancer and Other Solid Tumors

Date:

Monday, June 21

Time:

9:00 am – 11:00 am MT

The webcast of the presentation can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.

On June 14, 2021 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) reported the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied Radiology (Press release, Telix Pharmaceuticals, JUN 14, 2021, View Source [SID1234583973]). This website is specifically designed for healthcare professionals such as physicians and technologists, and features case studies, webinars, and technologist education.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The launch of TelixU coincides with this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, and with over 20 sessions on gallium-68 (68Ga), the website will be a welcome resource for those looking for more information about prostate specific membrane antigen (PSMA) targeted radiopharmaceuticals. "We are proud to support SNMMI and their endeavors to educate physicians and their membership," says Colin Hayward, MBBS FFPM, Chief Medical Officer, Telix Pharmaceuticals. "Our participation in this year’s Virtual Annual Meeting is an ideal platform to introduce this valuable resource."

The Case Studies section provides peer-to-peer insight about PSMA PET/CT1 imaging, whilst ‘Technologist Education’ is a wide-ranging resource for anyone delivering PSMA imaging services and includes patient considerations, PET/CT imaging protocols, and operational and workflow resources.

"Applied Radiology is delighted to support Telix in this endeavor," said Kieran Anderson, Vice President and Group Publisher at Anderson Publishing Ltd., publishers of Applied Radiology and Applied Radiation Oncology. "We have a long history of working closely with key opinion leaders and industry. We develop high-quality, informative, and engaging content, and TelixU is the latest example, as it builds on our continued commitment to the medical imaging community."

TelixU is intended for healthcare professionals only.

About Anderson Publishing

Anderson Publishing, Ltd. is a leading medical communications and publishing company dedicated to producing high-quality, informative, and engaging content for the medical imaging and radiation oncology communities. Its primary brands include Applied Radiology, in publication since 1971, and Applied Radiation Oncology, in publication since 2012. Together, they reach a global audience of over 60,000 radiologists, nuclear medicine physicians, radiation oncologists, physicists, radiation therapists, nuclear medicine technologists, radiologic technologists, radiology administrators, and related imaging professionals.

On June 14, 2021 Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) ("Isofol" or the "Company") reported that fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the "Rights Issue"), which ended on June 10, 2021, was oversubscribed (Press release, Isofol Medical, JUN 14, 2021, View Source [SID1234583958]). Due to the strong demand from strategic investors, a directed issue with deviation from the shareholders’ preferential rights of approximately SEK 100 million (the "Over-Allotment Option") was exercised. Through the Rights Issue and the Over-Allotment Option, Isofol will receive proceeds amounting to approximately SEK 500 million before transaction costs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Not for publication, distribution or release, directly or indirectly, in whole or in part, within or into the United Kingdom, US, Canada, Japan, Australia, Hong Kong, New Zealand or any other jurisdiction in which such publication, distribution or release may be contravening to any applicable laws or rules. Additional restrictions are applicable, please see "Important information" in the end of this press release.

The result of the Rights Issue of maximum 62,524,474 shares shows that 61,550,652 new shares, corresponding to approximately 98.4 percent of the Rights Issue, have been subscribed for with subscription rights. Additionally, 27,532,079 shares were subscribed for without subscription rights of which 973,822 shares, corresponding to 1.6 percent of the Rights Issue, have been allotted to investors that have subscribed for shares without subscription rights. The Rights Issue is thus oversubscribed. Allotment of shares subscribed for without subscription rights has been made in accordance with the resolved allotment principles. Notice of allotment of shares subscribed for without subscription rights will only be sent to those who have been allotted shares. Payment shall be made in accordance with the instructions on the contract note. Nominee-registered shareholders will receive notice of allotment and payment in accordance with the procedures of each nominee.

Due to the oversubscription of the Rights Issue, the Board of Directors of Isofol has exercised the Over-Allotment Option to meet additional demand from strategic investors through a directed issue of 15,625,000 new shares. The Over-Allotment Option was directed to a few reputable investors, broadening Isofol’s shareholder base.

Isofol’s CEO, Ulf Jungnelius, comments: "We are very happy and satisfied with the strong support that both existing and new shareholders have shown us in the rights issue that made it possible to exercise the over-allotment option. The rights issue in combination with the over-allotment Option provides Isofol with the financial resources required to complete the global Phase III AGENT study and secure funding beyond the submission of the application with the FDA."

Following the Rights Issue and Over-Allotment Option, Isofol’s share capital will increase by approximately SEK 2,392,767.2 to approximately SEK 4,945,252.1 and the number of shares in Isofol will increase by 78,149,474 shares to 161,515,440 shares.

The shares subscribed for with subscription rights are expected to be registered with the Swedish Companies Registration Office (the "SCRO") on or about June 15, 2021 and are expected to begin trading on Nasdaq First North Premier Growth Market on June 18, 2021.

The shares subscribed for without subscription rights and through exercise of the Over-Allotment Option are expected to be registered with the SCRO on or about June 24, 2021 and are expected to begin trading on Nasdaq First North Premier Growth Market on June 30, 2021.

Advisors

Carnegie Investment Bank AB (publ) and Pareto Securities AB act as Joint Bookrunners in connection with the Rights Issue and the potential Over-Allotment Option. Vinge law firm acts as legal adviser to Isofol, and Schjødt law firm acts as legal adviser to the Joint Bookrunners. Ashurst LLP acts as legal adviser to the Joint Bookrunners as to US securities law.

For further information, please contact

This is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on June 14, 2021.

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.